摘要
目的 研究血液透析疗法在急性淋巴细胞白血病甲氨蝶呤患儿中的应用效果。方法选取2017年8月-2021年8月在我院接受治疗的60例急性淋巴细胞白血病化疗后急性肾损伤患儿作为研究对象。患儿在常规治疗的基础上进行血液透析治疗,观察患儿治疗前后各项临床指标变化。结果 治疗后,患儿尿素氮由(40.65±4.47)mmol/L改善至(6.56±2.05)mmol/L;血肌酐由(142.21±6.23)umol/L改善至(105.32±3.29)umol/L;血尿酸由(221.24±6.35)umol/L改善至(206.35±3.28)umol/L;钙离子水平由(1.10±0.12)mmol/L升高至(1.16±0.11)mmol/L;总胆红素由(9.40±2.13)umol/L改善至(5.87±1.12)umol/L;甲氨蝶呤含量由(124.43±8.23)umol/L改善至(6.75±1.32)umol/L,差异存在统计学意义(P<0.05)。治疗后,患儿血红蛋白、白细胞、血小板、总蛋白、白蛋白、钠离子、钾离子、pH值等临床指标与治疗前相比无统计差异(P>0.05)。结论 将血液透析疗法应用于急性淋巴细胞白血病化疗后急性肾损伤患儿治疗中效果较好,可显著改善患儿肾功能,并有效清除体内甲氨蝶呤。
Objective: To study the effect of hemodialysis on children with acute lymphoblastic leukemia methotrexate. Methods: A total of 60 children with acute kidney injury after chemotherapy of acute lymphoblastic leukemia who were treated in our hospital from August 2017 to August 2021 were selected as the research subjects. The children were treated with hemodialysis on the basis of conventional treatment, and the changes of various clinical indicators were observed before and after treatment. Results: After treatment, the children’s blood urea nitrogen improved from(40.65±4.47) mmol/L to(6.56±2.05) mmol/L;serum creatinine improved from(142.21±6.23) umol/L to(105.32±3.29) umol/L;serum uric acid improved from(221.24±6.35) umol/L to(206.35±3.28) umol/L;calcium ion level increased from(1.10±0.12) mmol/L to(1.16±0.11) mmol/L;total bilirubin methotrexate content improved from(9.40±2.13) umol/L to(5.87±1.12) umol/L;methotrexate content improved from(124.43±8.23) umol/L to(6.75±1.32)umol/L, there was significantly statistical difference(P<0.05). After treatment, there was no statistical difference in the clinical indicators such as hemoglobin, leukocytes, platelets, total protein, albumin, sodium ion, potassium ion, pH value of the children compared with those before treatment(P>0.05). Conclusion: Hemodialysis is effective in the treatment of children with acute kidney injury after chemotherapy of acute lymphoblastic leukemia, which can effectively improve the renal function of children and effectively remove methotrexate from the body.
作者
何程明
HE Cheng-ming(Ganzhou People's Hospital,Ganzhou Jiangxi 341000,China)
出处
《透析与人工器官》
2022年第4期19-21,33,共4页
Chinese Journal of Dialysis and Artificial Organs
作者简介
通讯作者:何程明,E-mail:598095667@qq.com
